Opportunity
Simpler Grants.gov #PAR-26-129
NCI STRIPE Program Solicitation for Preclinical Radionuclide Research
Buyer
National Cancer Institute
Posted
March 11, 2026
Respond By
October 05, 2026
Identifier
PAR-26-129
NAICS
541715, 541714, 541713
The National Cancer Institute (NCI), part of the National Institutes of Health, is seeking research proposals for the Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) program. - Government Buyer: - National Cancer Institute (NCI), National Institutes of Health - Program Focus: - Multidisciplinary research on the biological effects of radiation from radionuclides in radiopharmaceutical therapy (RPT) - Use of advanced cancer biology and preclinical model systems - Goal: Improve understanding of how radionuclide-emitted radiation impacts normal tissues, tumor cells, and the tumor microenvironment - Project Types and Duration: - Exploratory/developmental projects (up to 2 years) - Full research projects (4 to 5 years) - Eligibility: - Open to government, nonprofit, business, educational, and foreign institutions - Notable Requirements: - No specific OEMs, vendors, products, or part numbers are specified - This is a grant opportunity for scientific research, not a procurement of goods or commercial services
Description
The National Cancer Institute (NCI) seeks to support research projects using advanced cancer biology and preclinical models to study the biological effects of radiation from radionuclides used in radiopharmaceutical therapy (RPT). The initiative aims to understand how different radionuclide-emitted radiation affects normal tissues, tumor cells, and the tumor microenvironment to improve therapeutic outcomes. Funded projects under the STRIPE program will integrate multiple disciplines to generate insights for new targeting strategies, optimized treatments, and combination approaches for RPT. Applicants may submit proposals for exploratory/developmental projects up to 2 years or research projects lasting 4 to 5 years. The program intends to broaden RPT research, lower entry barriers for cancer biology investigators, and accelerate data generation for more effective and personalized cancer therapies.